E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.
Breast Cancer ResSep 17, 2026 (epub)
Hiroshi Ishiguro, Yasuo Miyoshi, Hiroyuki Yasojima et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1 multicenter trial evaluated E7389-LF as a first-line chemotherapy in 26 Japanese patients with metastatic HER2-negative breast cancer. The study found an objective response rate of 30.8%, with a median progression-free survival of 8.1 months. Most patients experienced treatment-related adverse events, primarily alopecia and neutropenia.
Key findings
- Objective response rate was 30.8%, with 8 patients achieving confirmed partial responses.
- Median progression-free survival was 8.1 months overall.
- Most common treatment-related adverse events included alopecia (88.5%) and neutropenia (88.5%).
- Median overall survival was not reached at 22.7 months of follow-up.
Why it matters
The study highlights the potential of E7389-LF as a first-line treatment option for patients with HER2-negative breast cancer, addressing a critical need for effective therapies in this population.